NEW YORK (GenomeWeb News) – CovalX and Bruker's Daltonics division today announced an agreement to combine their technologies to support research into protein interactions and macromolecular characterization.
The deal will provide customers access to CovalX's High-Mass systems with Bruker Daltonics' MALDI mass spectrometers, a combination of technologies that the two firms said will result in "significantly improved detection capabilities in the 150-2,000 kDa range."
They added that in conjunction with CovalX's cross-linking kits for MALDI, the High-Mass system opens up new applications, including intact therapeutic protein aggregates, antibody-antigen interactions, and protein complex analysis.
"The interaction of both CovalX and Bruker technologies will allow the customers to perform protein-protein interaction studies on an advanced level," Ralf Schäfer, global product manager MALDI TOF MS of Bruker Daltonics Life Science and Clinical Division, said in a statement.
Financial and other terms of the deal were not disclosed.
The deal follows an announcement on Monday by Bruker that it signed an agreement with 3M Company to include patented 3M technology related to MALDI imaging into Bruker's products.
Covalx is based in Zürich, Switzerland, and its products are used for intact protein complex analysis by high mass MALDI-based technology. Its US subsidiary is headquartered in Saugus, Mass.